Defined Terms Section Sample Clauses

Defined Terms Section. Certificate Section 2.5.2 CGCL Recitals Closing Section 1.2 Closing Date Section 1.2 Code Recitals Combination Cash Election Section 2.2.1 Combination Stock Election Section 2.2.1 Community Reinvestment Act Section 3.7(c) Confidentiality Agreement Section 6.2 Control Transaction Section 11.2 CVBF Preamble CVBF Affiliated Shareholders Recitals CVBF Articles Section 4.2 CVBF Balance Sheet Section 4.9(c) CVBF Bank Recitals CVBF Benefit Plan Section 7.4(a) CVBF Board Section 4.5(a) CVBF Board Approval Section 4.5(b) CVBF Board Recommendation Section 5.3(b) CVBF Bylaws Section 4.2 CVBF Common Stock Certificates Section 2.4(a) CVBF Confidential Disclosure Schedule Article IV Preamble CVBF Fairness Opinion Section 4.26 CVBF Material Contract Section 4.15 CVBF Options Section 7.1(b) CVBF Permits Section 4.8(a) CVBF Property Section 4.20 CVBF SEC Filings Section 4.9(a) CVBF Shares Section 2.1(a) CVBF Termination Fee Section 11.2(c) Effective Time Section 1.2 Election Section 2.2.1 Election Deadline Section 2.2.2 Election Form Section 2.2.1 Election Form Record Date Section 2.2.1 Exchange Agent Section 2.4(a) Exchange Fund Section 2.5.1 FCBS Preamble FCBS Affiliated Shareholders Recitals FCBS Affiliates Section 6.6 FCBS Articles Section 3.2 FCBS Balance Sheet Section 3.8(c) FCBS Bank Recitals FCBS Board Approval Section 3.5(b) FCBS Board Recommendation Section 5.3(b) FCBS Bylaws Section 3.2 FCBS Confidential Disclosure Schedule Article III Preamble FCBS Employees Section 7.4(a) FCBS Fairness Opinion Section 3.26 FCBS Financial Advisor Section 3.26 FCBS Filings List Section 3.8(a) FCBS Filings Section 3.8(a) FCBS Material Contract Section 3.14 FCBS Option Shares Section 3.3(a) FCBS Options Section 2.5 FCBS Permits Section 3.7 FCBS Property Section 3.20 FCBS Shareholders’ Meeting Section 5.2 FCBS Stock Certificates Section 2.4(b) FCBS Termination Fee Section 11.2(b) Governing Law Section 12.13 Hearing Section 5.2(a) Hearing Notice Section 5.2(a) Holding Company Merger Recitals Indemnified Liabilities Section 7.5(a) Indemnified Persons Section 7.5(a) Indemnifying Party Section 7.5(a) Liens Section 3.4 Mailing Date Section 2.2.1 Multiemployer Plan Section 3.11(b) Option Payment Section 2.6 Option Payments Section 2.6 Permit Application Section 5.2(a) Prohibited Transaction Section 3.11(b) Registration Statement on Form S-4 Section 5.2(b) Regulatory Authority Section 3.8(d) Representatives Section 6.2 Stock Election Section 2.2.1 Stock Proration Factor Section 2.2.3(a)(i...

Defined Terms Section. Signing Backlog 2.5(b) Software License Agreement 1.8(b)(ix) Specified IP 9.11 Subcontract Agreement 1.8(b)(vi) Sublease 1.8(b)(viii) Tax Contest 8.4(b)(i) Tax Returns Article X Taxes Article X Taxing Authority 8.4(a) Third Party Article X Trade Compliance Laws Article X Transaction Agreements Article X Transfer Taxes 8.1(c) Transition Services Agreement 1.8(b)(x) U.S. Acquired Assets 1.1 U.S. Assumption Agreement 1.4(a) U.S. Buyer Preamble (a) U.S. Buyer Plans 9.3(a)(i)(A) U.S. New Buyer Employees 9.3(a)(i)(A) Unaudited Financial Statements 2.5(a) Vendors 2.19 WARN 9.3(h)(iv)

Defined Terms Section. Claims 11.1 Combination Product Dispute 1.55 Commercialization Plan 6.2(a) Competing Program 2.5 Confidentiality Agreement 1.20 CTD 1.17 Development Notice 4.7(b) Development Opt-In Notice 4.7(b) Development Participation Costs Dispute 4.7(b) Development Participation Right 4.7(b) Development Plan 4.2 Dispute 14.1 Effective Date Preamble Enforcing Party 9.4(b) GAAP 1.1 GDP 3.2(a)(vi) GlycoMimetics Preamble GlycoMimetics Indemnitees 11.2 GlycoMimetics Inventions 9.1(d)(i) GlycoMimetics Partner 2.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Initial Development Plan 4.2 Joint Clinical Trial Costs Dispute 4.3(b)(iii) Joint Development Committee (JDC) 3.2(a) Joint Inventions 9.1(d)(iii) Licensed ▇▇▇▇ 9.6(a) Losses 11.1 Manufacturing Technology Transfer Agreement 7.2 NDA 1.54 Party Preamble Pharmacovigilance Agreement 5.8 Product Materials 4.7(a) Region 1.7 Remedial Action 5.9 Reversion Background IP 13.6(f) Reversion Collaboration IP 13.6(f) [***] [***] Royalty Term 8.4(b) Rules 14.2(a) SEC 12.3(c) Study 4.3(b)(i) Supply Agreement 7.1 Term 13.1 Third Party Infringement Actions 9.5 Step-In Rights 9.2(d) VAT 8.10(c)

Defined Terms Section. Option Recitals Party Preamble Profit-Sharing Agreement Recitals Receiving Party 4.1(a) Royalty Term 3.6(a) Settlement Payments 2.1(d) Transferred Regulatory Filings 2.4 TSA Recitals VAT 3.12(b)

Defined Terms Section. Competing Program 2.9(a) Compound Invention 11.1(b)(i) Development Budget 4.2 Disputed Matter 16.2 Divest 2.8(c) Excess Funds 4.5(a)

Defined Terms Section. Company Patents 9.2(b) Enforcing Party 9.3(c) Infringement Actions 9.4 Company Housemarks 9.6(b) Company Indemnitees 11.1 Losses 11.1 Claims 11.1 KemPharm Indemnitees 11.2 Indemnified Party 11.3 Indemnifying Party 11.3 Term 13.1 Bankruptcy Event 13.5(a) Bankrupt Party 13.5(b) Code 13.5(b) Non-Bankrupt Party 13.5(b) Payment Assignment 15.5(c) Payment Assignment Notice 15.5.(c) Exclusive Period 15.5(c) Payment ROFR 15.5(c)

Defined Terms Section. Licensee Preamble Licensee Development Plan 4.3(b) Licensee Indemnitees 13.1 Licensee Territory Data 5.3(a) Licensee Withholding Tax Action 8.8(c) Material Safety Event 11.2(c) Necessary Third Party IP Rights 2.5(a) Non-publishing Party 10.3(e) Party Preamble Parties Preamble [***] [***] Pharmacovigilance Agreement 5.5(c) Product Infringement 9.3(a) Product Marks 7.5 Product Specific Patent 9.2(a) Publishing Party 10.3(e) Receiving Party 10.1(a) Regulatory Milestone Event 8.2(a) Regulatory Milestone Payment 8.2(a) Royalty Term 8.4(d) Sales Milestone Event 8.3(a) Sales Milestone Payment 8.3(a) Segregation Requirements 2.4(b)(i) Sole Inventions 9.1(a) Supply Agreement 6.2 Term 11.1 Third Party IP Notice 2.5(a) Upstream License 2.5(b)

Defined Terms Section. Alliance Manager 3.1 Auditor 10.4(c) Bankruptcy Event 13.5 Bankrupt Party 15.13 Claims 11.1 Clinical Supply Agreement 7.1 Commercialization Plan 6.2(a) Commercial Supply Agreement 7.2(a) Competing Program 15.5(b) Confidentiality Agreement 1.20 DMF 5.1(b) Effective Date Preamble Enforcing Party 9.4(c) Executive Officer 14.1 First Supplemental Development Plan 4.2 GAAP 1.1 Global Development Plan 4.3(d) Global Strategy 4.3(d) Global Territory Expansion Opportunity 6.6 GQP Agreement 5.1(b) ICC 14.2 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Infringement Action 9.5 Initial Development Plan 4.2 Initial Purchase Price Payment 8.5(a)(i) JGAAP 1.1 Joint Inventions 9.1(c)(iii) Joint Steering Committee 3.2(a) Kaken Preamble Kaken Housemarks 9.6(b) Kaken Indemnitees 11.1 Kaken Inventions 9.1(c)(ii) Kaken Product Mark 9.6(a) Kaken Sublicense Agreement 2.1(c) Lilly 1.86 Losses 11.1 Major Spruce Partner 2.2 Manufacturing Technology Transfer Agreement 7.2(b) NDA 1.56 Non-Bankrupt Party 15.13 Party Preamble Payment 8.9(b) Pharmacovigilance Agreement 5.8 Product Materials 4.6 Reconciliation Amount 8.5(a)(i) Remedial Action 5.9 Right of Reference 5.5 ROFN 6.6 ROFN Exercise Period 6.6 ROFN Exercise Notice 6.6 ROFN Negotiation Period 6.6 ROFN Offer Notice 6.6 Royalty Term 8.4(b) SEC 12.3(c) Spruce Preamble Spruce Indemnitees 11.2 Spruce Inventions 9.1(c)(i) Spruce Partner 2.2 Step-In Rights 9.2(e) Tax Changing Decision 8.9(b) Tax Documents 8.1 Term 13.1 Territory Development Plan 4.2 Territory Expansion Opportunity 6.6 Transfer Price 8.4(a)(i) Working Group 3.5

Defined Terms Section. Company Preamble Company Disclosure Letter 5.1 Company Expenses 8.5(c) Company Expenses Cap 8.5(c) Company Financial Statements 5.1(e)(v) Company Material Adverse Effect 5.1(a)(ii) Company Material Contract 5.1(q)(i)(M) Company Plans 5.1(h)(i) Company Recommendation 5.1(c)(ii) Company Required Governmental Approvals 5.1(d)(i) Company Requisite Vote 5.1(c)(i) Company SEC Reports 5.1(e)(i) Compliant 6.14(f)(vi) Confidentiality Agreement 9.7